A recent study indicates that individuals who stop using new GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who end traditional lifestyle programs.
Research printed in a prominent health publication demonstrates that while obese people can lose about a fifth of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users buying these drugs need to be informed of the potential of quick rebound weight gain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to original weight in about a year and a half.
Weighing Therapies
The study, which examined dozens of studies involving thousands of participants, compared the outcomes of these new drugs with conventional dieting.
The team emphasize that people who shed pounds through lifestyle changes alone typically experience a slower weight regain—around 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Doctors believe the mechanism of the drugs accounts for the accelerated weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations several times higher than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement means appetite is uncontrolled, making overeating much more probable."
An Ongoing Issue?
Health authorities recommend the jabs for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, considering the significant potential of weight regain, the treatment might need to be life-long.
This view is echoed by drug manufacturers, who state that the findings "underscore the long-term character of obesity," comparing it to managing diseases like hypertension.
Patient Accounts
Individuals who have stopped the medication describe a intense return of cravings.
"It felt as if a switch that goes on and you become extremely hungry," recalled a patient.
The struggle is worsened if patients have not adopted lasting dietary or behavioural modifications during therapy.
Growing Adoption
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial.
- Use is higher among females than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a magic solution and long-term success relies on ongoing behavioural support.
